Lung Cancer | Specialty

Small Cell Lung Cancer: Interpreting Data From IMpower133

December 17th 2019

Current Frontline Management of Small Cell Lung Cancer

December 17th 2019

Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC

December 16th 2019

Treatment with entrectinib led to an overall response rate of 77% and a median duration of response of 24.6 months in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated findings of a pooled analysis published in Lancet Oncology.

Dr. Fidler on the Utility of Dacomitinib in EGFR-Mutant NSCLC

December 16th 2019

Mary J. Fidler, MD, discusses the utility of dacomitinib (Vizimpro) in patients with EGFR-mutant non–small cell lung cancer.

Dr. Saxena on Treatment Options in ALK+ NSCLC

December 13th 2019

Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.

Dr. Drilon on Treatment Selection Considerations in ALK+ NSCLC

December 12th 2019

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.

Investigators Test Tumor-Treating Fields in Lung Cancer

December 11th 2019

Investigators are attempting to advance the late-stage non–small cell lung cancer treatment paradigm by combining an emerging antimitotic modality with standard-of-care therapies in the phase III LUNAR trial.

Dr. Parikh on KRAS Inhibitors in Lung Cancer

December 10th 2019

Kaushal Parikh, MD, MBBS, discusses the KRAS inhibitors AMG 510 and MRTX849 in lung cancer.

Dr. Rizk on Eligibility Criteria for Surgical Resection in Lung Cancer

December 10th 2019

Nabil P. Rizk, MD, MS, MPH, discusses criteria for surgical resection in lung cancer.

Dr. Hudson on the Utility of Liquid Biopsy in Metastatic Lung Cancer

December 5th 2019

Kathryn E. Hudson, MD, discusses the utility of liquid biopsies in metastatic lung cancer.

Checking Out Emerging Approaches in Lung Cancer Treatment in Chicago

December 4th 2019

We traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer, which featured insights from the University of Chicago faculty.

FDA Approves Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel for Nonsquamous NSCLC

December 4th 2019

The FDA has approved atezolizumab in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with metastatic nonsquamous non–small cell lung cancer who do not harbor EGFR or ALK molecular aberrations.

Targeted Therapies Continue to Evolve in Metastatic NSCLC

December 2nd 2019

The proliferation of targeted therapies in non–small cell lung cancer has helped improve overall survival for patients with metastatic disease and illustrates the importance of molecular testing,

Genomic Era Trials Drive Discovery

December 2nd 2019

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

FDA Grants Durvalumab Priority Review for Frontline Small Cell Lung Cancer

December 2nd 2019

The FDA has granted a priority review designation to a supplemental Biologics License Application for durvalumab for the frontline treatment of patients with extensive-stage small cell lung cancer.

Liquid Biopsies Move Closer to Broad Clinical Adoption

December 1st 2019

Liquid biopsy technologies have made substantial headway in recent years, sparking booming commercial interest in the development of potential clinical applications.

Dr. Levy on First-Line Treatment for Nondriver NSCLC

November 28th 2019

Benjamin P. Levy, MD, discusses first-line treatment for patients with nondriver non–small cell lung cancer.

Osimertinib Now Standard in Frontline EGFR+ NSCLC, But Potential for Progress Remains

November 27th 2019

Mary J. Fidler, MD, discusses how recent research has impacted the EGFR-mutant non–small cell lung cancer landscape.

Dr. Perez-Soler on the Utility of Liquid Biopsy in Lung Cancer

November 27th 2019

Roman Perez-Soler, MD, discusses the utility of liquid biopsy in lung cancer.

Pembrolizumab Regimen Approved in China for Frontline Squamous NSCLC

November 27th 2019

China’s National Medical Products Administration has approved the combination of pembrolizumab plus carboplatin and paclitaxel for the first-line treatment of patients with metastatic squamous non–small cell lung cancer.